{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:33:17Z","timestamp":1793424797032,"version":"4.5.0"},"reference-count":66,"publisher":"Medical Association of Nippon Medical School","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2026,10,20]]},"DOI":"10.1272\/jnms.jnms.2026_93-510","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T22:09:53Z","timestamp":1787522993000},"page":"351-360","source":"Crossref","is-referenced-by-count":0,"title":["Cell-Based Therapies and Drug Repurposing in Stroke"],"prefix":"10.1272","volume":"93","author":[{"given":"Satoshi","family":"Suda","sequence":"first","affiliation":[{"name":"Department of Neurology, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Katano","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Nito","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nippon Medical School"},{"name":"Depatment of Clinical Laboratory Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21","reference":[{"key":"1","unstructured":"1. GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024 Oct;23 (10):973\u20131003."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Toyoda K, Yoshimura S, Nakai M, et al. Twenty-year change in severity and outcome of ischemic and hemorrhagic strokes. JAMA Neurol. 2022 Jan 1;79 (1):61\u20139.","DOI":"10.1001\/jamaneurol.2021.4346"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rajsic S, Gothe H, Borba HH, et al. Economic burden of stroke: a systematic review on post-stroke care. Eur J Health Econ. 2019 Feb;20 (1):107\u201334.","DOI":"10.1007\/s10198-018-0984-0"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Luengo-Fernandez R, Paul NL, Gray AM, et al. Population-based study of disability and institutionalization after transient ischemic attack and stroke: 10-year results of the Oxford Vascular Study. Stroke. 2013 Oct;44 (10):2854\u201361.","DOI":"10.1161\/STROKEAHA.113.001584"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Campbell BCV, Khatri P. Stroke. Lancet. 2020 Jul 11;396 (10244):129\u201342.","DOI":"10.1016\/S0140-6736(20)31179-X"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Dhir N, Medhi B, Prakash A, Goyal MK, Modi M, Mohindra S. Pre-clinical to clinical translational failures and current status of clinical trials in stroke therapy: a brief review. Curr Neuropharmacol. 2020;18 (7):596\u2013612.","DOI":"10.2174\/1570159X18666200114160844"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in phase II\/III acute ischemic stroke trials. Stroke. 2009 Feb;40 (2):577\u201381.","DOI":"10.1161\/STROKEAHA.108.524330"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 2002 Oct;1 (6):383\u20136.","DOI":"10.1016\/S1474-4422(02)00164-3"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Nito C, Suda S, Nitahara-Kasahara Y, Okada T, Kimura K. Dental-pulp stem cells as a therapeutic strategy for ischemic stroke. Biomedicines. 2022 Mar 22;10 (4):737.","DOI":"10.3390\/biomedicines10040737"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nakajima M, Nito C, Sowa K, et al. Mesenchymal stem cells overexpressing Interleukin-10 promote neuroprotection in experimental acute ischemic stroke. Mol Ther Methods Clin Dev. 2017 Jun 23;6:102\u201311.","DOI":"10.1016\/j.omtm.2017.06.005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Suda S, Yang B, Schaar K, et al. Autologous bone marrow mononuclear cells exert broad effects on short- and long-term biological and functional outcomes in rodents with intracerebral hemorrhage. Stem Cells Dev. 2015 Dec 1;24 (23):2756\u201366.","DOI":"10.1089\/scd.2015.0107"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Suda S, Shimazaki K, Ueda M, et al. Combination therapy with bone marrow stromal cells and FK506 enhanced amelioration of ischemic brain damage in rats. Life Sci. 2011 Jul 4;89 (1-2):50\u20136.","DOI":"10.1016\/j.lfs.2011.05.001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nito C, Sowa K, Nakajima M, et al. Transplantation of human dental pulp stem cells ameliorates brain damage following acute cerebral ischemia. Biomed Pharmacother. 2018 Dec;108:1005\u201314.","DOI":"10.1016\/j.biopha.2018.09.084"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sowa K, Nito C, Nakajima M, et al. Impact of dental pulp stem cells overexpressing hepatocyte growth factor after cerebral ischemia\/reperfusion in rats. Mol Ther Methods Clin Dev. 2018 Aug 4;10:281\u201390.","DOI":"10.1016\/j.omtm.2018.07.009"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Suda S, Ueda M, Nito C, et al. Valproic acid ameliorates ischemic brain injury in hyperglycemic rats with permanent middle cerebral occlusion. Brain Res. 2015 May 5;1606:1\u20138.","DOI":"10.1016\/j.brainres.2015.02.013"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Suda S, Katsura KI, Saito M, Kamiya N, Katayama Y. Valproic acid enhances the effect of bone marrow-derived mononuclear cells in a rat ischemic stroke model. Brain Res. 2014 May 27;1565:74\u201381.","DOI":"10.1016\/j.brainres.2014.04.011"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Suda S, Katsura K, Kanamaru T, Saito M, Katayama Y. Valproic acid attenuates ischemia-reperfusion injury in the rat brain through inhibition of oxidative stress and inflammation. Eur J Pharmacol. 2013 May 5;707 (1-3):26\u201331.","DOI":"10.1016\/j.ejphar.2013.03.020"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yang L, Wang Y, Zhang C, Chen T, Cheng H. Perampanel, an AMPAR antagonist, alleviates experimental intracerebral hemorrhage-induced brain injury via necroptosis and neuroinflammation. Mol Med Rep. 2021 Aug;24 (2):544.","DOI":"10.3892\/mmr.2021.12183"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sharma H, Reeta KH, Sharma U, Suri V, Singh S. AMPA receptor modulation through sequential treatment with perampanel and aniracetam mitigates post-stroke damage in experimental model of ischemic stroke. Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec;396 (12):3529\u201345.","DOI":"10.1007\/s00210-023-02544-z"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kawakita F, Nakano F, Kanamaru H, Asada R, Suzuki H. Anti-apoptotic effects of AMPA receptor antagonist perampanel in early brain injury after subarachnoid hemorrhage in mice. Transl Stroke Res. 2024 Apr;15 (2):462\u201375.","DOI":"10.1007\/s12975-023-01138-4"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Nakajima M, Suda S, Sowa K, et al. AMPA receptor antagonist perampanel ameliorates post-stroke functional and cognitive impairments. Neuroscience. 2018 Aug 21;386:256\u201364.","DOI":"10.1016\/j.neuroscience.2018.06.043"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Qin C, Yang S, Chu YH, et al. Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022 Jul 6;7 (1):215.","DOI":"10.1038\/s41392-022-01064-1"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Yamaguchi S, Horie N, Satoh K, et al. Age of donor of human mesenchymal stem cells affects structural and functional recovery after cell therapy following ischaemic stroke. J Cereb Blood Flow Metab. 2018 Jul;38 (7):1199\u2013212.","DOI":"10.1177\/0271678X17731964"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Wang Z, Wang X, Liao Y, Chen G, Xu K. Immune response treated with bone marrow mesenchymal stromal cells after stroke. Front Neurol. 2022 Sep 20;13:991379.","DOI":"10.3389\/fneur.2022.991379"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Andres RH, Horie N, Slikker W, et al. Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain. Brain. 2011 Jun;134 (Pt 6):1777\u201389.","DOI":"10.1093\/brain\/awr094"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Horie N, Hiu T, Nagata I. Stem cell transplantation enhances endogenous brain repair after experimental stroke. Neurol Med Chir (Tokyo). 2015;55 Suppl 1:107\u201312.","DOI":"10.2176\/nmc.ra.2014-0271"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Singh D, Gupta S, Verma I, Morsy MA, Nair AB, Ahmed AF. Hidden pharmacological activities of valproic acid: a new insight. Biomed Pharmacother. 2021 Oct;142:112021.","DOI":"10.1016\/j.biopha.2021.112021"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Chen PS, Wang CC, Bortner CD, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience. 2007 Oct 12;149 (1):203\u201312.","DOI":"10.1016\/j.neuroscience.2007.06.053"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Suda S, Kimura K. Therapeutic potential of AMPA receptor antagonist perampanel against cerebral ischemia: beyond epileptic disorder. Neural Regen Res. 2019 Sep;14 (9):1525\u20136.","DOI":"10.4103\/1673-5374.255964"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Chen T, Yang LK, Zhu J, Hang CH, Wang YH. The AMPAR antagonist perampanel regulates neuronal necroptosis via Akt\/GSK3\u03b2 signaling after acute traumatic injury in cortical neuron. CNS Neurol Disord Drug Targets. 2021 Oct 26;20 (3):266\u201372.","DOI":"10.2174\/1871527319666201001110937"},{"issue":"03","key":"31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.21926\/obm.neurobiol.2403239","volume":"8","author":"R Anaya-Fernandez","year":"2024","unstructured":"31. Anaya-Fernandez R, Anaya-Prado R, Anaya-Fernandez MM, et al. Oxidative Stress in Cerebral Ischemia\/Reperfusion Injury. OBM Neurobiology. 2024;8 (03):239.","journal-title":"OBM Neurobiology","ISSN":"https:\/\/id.crossref.org\/issn\/2573-4407","issn-type":"print"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Zayed M, Elwakeel E, Ezzat P, Jeong BH. Mesenchymal stem cell-derived exosomes as a potential therapeutic strategy for ferroptosis. Stem Cell Res Ther. 2025 Jul 15;16 (1):368.","DOI":"10.1186\/s13287-025-04511-2"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kumar MA, Baba SK, Sadida HQ, et al. Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther. 2024 Feb 5;9 (1):27.","DOI":"10.1038\/s41392-024-01735-1"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Wang ZF, Fessler EB, Chuang DM. Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacol Sin. 2011 Dec;32 (12):1433\u201345.","DOI":"10.1038\/aps.2011.140"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ulas M, Gokay Argadal O, Bardas Ozkan E. Targeting oxidative stress and metal imbalance in cerebral ischemia: the neuroprotective role of sodium valproate. Sci Rep. 2025 Jul 28;15 (1):27529.","DOI":"10.1038\/s41598-025-12425-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Neves D, Salazar IL, Almeida RD, Silva RM. Molecular mechanisms of ischemia and glutamate excitotoxicity. Life Sci. 2023 Sep 1;328:121814.","DOI":"10.1016\/j.lfs.2023.121814"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Kurozumi K, Nakamura K, Tamiya T, et al. Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther. 2005 Jan;11 (1):96\u2013104.","DOI":"10.1016\/j.ymthe.2004.09.020"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Pickell Z, Williams AM, Alam HB, Hsu CH. Histone deacetylase inhibitors: a novel strategy for neuroprotection and cardioprotection following ischemia\/reperfusion injury. J Am Heart Assoc. 2020 Jun 2;9 (11):e016349.","DOI":"10.1161\/JAHA.120.016349"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39. Yang Y, Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke. 2011 Nov;42 (11):3323\u20138.","DOI":"10.1161\/STROKEAHA.110.608257"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Xin H, Li Y, Liu Z, et al. MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells. 2013 Dec;31 (12):2737\u201346.","DOI":"10.1002\/stem.1409"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Barzegar M, Wang Y, Eshaq RS, et al. Human placental mesenchymal stem cells improve stroke outcomes via extracellular vesicles-mediated preservation of cerebral blood flow. EBioMedicine. 2021 Jan;63:103161.","DOI":"10.1016\/j.ebiom.2020.103161"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Tian H, Yang X, Zhao J, et al. Hypoxia-preconditioned bone marrow mesenchymal stem cells improved cerebral collateral circulation and stroke outcome in mice. Arterioscler Thromb Vasc Biol. 2023 Jul;43 (7):1281\u201394.","DOI":"10.1161\/ATVBAHA.122.318559"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Cho DH, Park JH, Joo Lee E, et al. Valproic acid increases NO production via the SHP-TP1-CDK5-eNOS-Ser (116) signaling cascade in endothelial cells and mice. Free Radic Biol Med. 2014 Nov;76:96\u2013106.","DOI":"10.1016\/j.freeradbiomed.2014.07.043"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Perversi F, Costa C, Labate A, et al. The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy. Front Neurol. 2023 Jul 6;14:1182304.","DOI":"10.3389\/fneur.2023.1182304"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci. 2009 Dec;10 (12):861\u201372.","DOI":"10.1038\/nrn2735"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Oki K, Tatarishvili J, Wood J, et al. Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain. Stem Cells. 2012 Jun;30 (6):1120\u201333.","DOI":"10.1002\/stem.1104"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47. Horie N, Pereira MP, Niizuma K, et al. Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair. Stem Cells. 2011 Feb;29 (2):274\u201385.","DOI":"10.1002\/stem.584"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009 Nov;32 (11):591\u2013601.","DOI":"10.1016\/j.tins.2009.06.002"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 May;16 (5):360\u20138.","DOI":"10.1016\/S1474-4422(17)30046-7"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Houkin K, Osanai T, Uchiyama S, et al. Allogeneic stem cell therapy for acute ischemic stroke: the phase 2\/3 TREASURE randomized clinical trial. JAMA Neurol. 2024 Feb 1;81 (2):154\u201362.","DOI":"10.1001\/jamaneurol.2023.5200"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Suda S, Nito C, Ihara M, et al. Randomised placebo-controlled multicentre trial to evaluate the efficacy and safety of JTR-161, allogeneic human dental pulp stem cells, in patients with Acute Ischaemic stRoke (J-REPAIR). BMJ Open. 2022 May 24;12 (5):e054269.","DOI":"10.1136\/bmjopen-2021-054269"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Niizuma K, Osawa SI, Endo H, et al. Randomized placebo-controlled trial of CL2020, an allogenic muse cell-based product, in subacute ischemic stroke. J Cereb Blood Flow Metab. 2023 Dec;43 (12):2029\u201339.","DOI":"10.1177\/0271678X231202594"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Kalladka D, Sinden J, Pollock K, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet. 2016 Aug 20;388 (10046):787\u201396.","DOI":"10.1016\/S0140-6736(16)30513-X"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Muir KW, Bulters D, Willmot M, et al. Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2). J Neurol Neurosurg Psychiatry. 2020 Apr;91 (4):396\u2013401.","DOI":"10.1136\/jnnp-2019-322515"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Savitz SI, Cox CS Jr. Cell-based therapies for neurological disorders - the bioreactor hypothesis. Nat Rev Neurol. 2023 Jan;19 (1):9\u201318.","DOI":"10.1038\/s41582-022-00736-4"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Mazzocchetti P, Mancini A, Sciaccaluga M, et al. Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. Neurobiol Dis. 2020 Jul;140:104848.","DOI":"10.1016\/j.nbd.2020.104848"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Nakamichi Y, Ichibayashi R, Watanabe M, et al. Improved neurological outcome of perampanel for hypoxic-ischemic encephalopathy in patients after out-of-hospital cardiac arrest resuscitation. Cureus. 2023 Dec 31;15 (12):e51392.","DOI":"10.7759\/cureus.51392"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Lyden PD, Diniz MA, Bosetti F, et al. A multi-laboratory preclinical trial in rodents to assess treatment candidates for acute ischemic stroke. Sci Transl Med. 2023 Sep 20;15 (714):eadg8656.","DOI":"10.1126\/scitranslmed.adg8656"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Ayata C, Bath PM, Planas AM, et al. Preclinical ischemic stroke multicenter (PRISM) trials collective statement: opportunities, challenges, and recommendations for a new era. Stroke. 2026 Jan;57 (1):e12\u201340.","DOI":"10.1161\/STROKEAHA.125.052056"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Liebeskind DS, Derdeyn CP, Wechsler LR; STAIR X Consortium. STAIR X: Emerging Considerations in Developing and Evaluating New Stroke Therapies. Stroke. 2018 Sep;49 (9):2241\u20137.","DOI":"10.1161\/STROKEAHA.118.021424"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Kawabori M, Shichinohe H, Kuroda S, Houkin K. Clinical Trials of Stem Cell Therapy for Cerebral Ischemic Stroke. Int J Mol Sci. 2020 Oct 6;21 (19):7380.","DOI":"10.3390\/ijms21197380"},{"key":"62","doi-asserted-by":"publisher","unstructured":"62. Mishra MK, Kukal S, Paul PR, et al. Insights into structural modifications of valproic acid and their pharmacological profile. Molecules. 2021 Dec 24;27 (1):104.","DOI":"10.3390\/molecules27010104"},{"key":"63","unstructured":"63. Fan PF, Zhuo C, Huang M. Efficacy and safety of perampanel for epilepsy: a systematic review and meta-analysis of real-world studies. Eur Rev Med Pharmacol Sci. 2023 Jul;27 (13):6027\u201339."},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Yoon HY, Ahn MH, Yee J, Lee N, Han JM, Gwak HS. Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis. Eur J Clin Pharmacol. 2020 Aug;76 (8):1053\u20138.","DOI":"10.1007\/s00228-020-02872-6"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Spellicy SE, Hess DC. Recycled Translation: Repurposing Drugs for Stroke. Transl Stroke Res. 2022 Dec;13 (6):866\u201380.","DOI":"10.1007\/s12975-022-01000-z"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Suda S, Nito C, Yokobori S, et al. Recent Advances in Cell-Based Therapies for Ischemic Stroke. Int J Mol Sci. 2020 Sep 14;21 (18):6718.","DOI":"10.3390\/ijms21186718"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/93\/5\/93_JNMS.2026_93-510\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:11:23Z","timestamp":1793423483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/93\/5\/93_JNMS.2026_93-510\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2026_93-510","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"article-number":"JNMS.2026_93-510"}}